Publisher
Springer Science and Business Media LLC
Reference10 articles.
1. Mok, C. C. Treat-to-target in systemic lupus erythematosus: are we there yet? Expert Rev. Clin. Pharmacol. 9, 675–80 (2016).
2. Merrill, J. T. et al. The Biomarkers of Lupus Disease study: a bold approach may mitigate interference of background immunosuppressants in clinical trials. Arthritis Rheumatol.
http://dx.doi.org/10.1002/art.40086
, (2017).
3. van Vollenhoven, R. F. et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann. Rheum. Dis. 71, 1343–1349 (2012).
4. Merrill, J. T. et al. Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann. Rheum. Dis. 75, 332–340 (2016).
5. Merrill, J. T. et al. Efficacy and safety of atacicept in patients with systemic lupus erythematosus: results of a 24-week randomized, placebo-controlled, phase IIb study [abstract]. Arthritis Rheumatol. 68 (Suppl. 10), 12L (2016).
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献